Related Experiment Videos
[Chemotherapy for non-small cell lung cancer]
Nihon Kyobu Shikkan Gakkai Zasshi
|December 1, 1996
Summary
Cisplatin-based chemotherapy significantly improves survival for non-small cell lung cancer patients. Combining chemotherapy with radiotherapy offers better outcomes for locally advanced disease.
Area of Science:
- Oncology
- Medical Chemistry
Background:
- Cisplatin-based combination chemotherapy is a cornerstone in treating non-small cell lung cancer (NSCLC).
- Meta-analyses confirm reduced mortality with chemotherapy versus supportive care for unresectable NSCLC.
Purpose of the Study:
- To review the efficacy of cisplatin-based chemotherapy and novel agents in NSCLC treatment.
- To evaluate combined modality treatments involving chemotherapy and radiotherapy.
Main Methods:
- Review of meta-analyses of clinical trials comparing cisplatin-based chemotherapy with supportive care.
- Analysis of randomized studies comparing radiotherapy alone versus combined radiotherapy and cisplatin-based chemotherapy for Stage III NSCLC.
- Examination of emerging chemotherapeutic agents and their combinations.
Main Results:
- Cisplatin combination chemotherapy demonstrated a survival benefit in patients with non-resectable NSCLC.
- Combined chemoradiotherapy significantly improved survival and long-term outcomes in locally advanced NSCLC (Stage III).
- Newer agents, including vinorelbine, paclitaxel, and gemcitabine, show promise, with some reaching Phase III trials.
Conclusions:
- Cisplatin-based chemotherapy regimens, particularly in combination with novel agents, offer significant therapeutic potential for NSCLC.
- Combined modality treatments integrating platinum compounds with novel agents and radiotherapy represent a promising future direction for NSCLC management.